Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium
-
Published:2020-10-12
Issue:1
Volume:11
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Sajuthi Satria P., DeFord PeterORCID, Li Yingchun, Jackson Nathan D., Montgomery Michael T.ORCID, Everman Jamie L.ORCID, Rios Cydney L., Pruesse Elmar, Nolin James D.ORCID, Plender Elizabeth G., Wechsler Michael E., Mak Angel C. Y.ORCID, Eng Celeste, Salazar Sandra, Medina Vivian, Wohlford Eric M., Huntsman Scott, Nickerson Deborah A., Germer Soren, Zody Michael C., Abecasis GonçaloORCID, Kang Hyun Min, Rice Kenneth M.ORCID, Kumar Rajesh, Oh SamORCID, Rodriguez-Santana Jose, Burchard Esteban G., Seibold Max A.ORCID
Abstract
AbstractCoronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, an emerging virus that utilizes host proteins ACE2 and TMPRSS2 as entry factors. Understanding the factors affecting the pattern and levels of expression of these genes is important for deeper understanding of SARS-CoV-2 tropism and pathogenesis. Here we explore the role of genetics and co-expression networks in regulating these genes in the airway, through the analysis of nasal airway transcriptome data from 695 children. We identify expression quantitative trait loci for both ACE2 and TMPRSS2, that vary in frequency across world populations. We find TMPRSS2 is part of a mucus secretory network, highly upregulated by type 2 (T2) inflammation through the action of interleukin-13, and that the interferon response to respiratory viruses highly upregulates ACE2 expression. IL-13 and virus infection mediated effects on ACE2 expression were also observed at the protein level in the airway epithelium. Finally, we define airway responses to common coronavirus infections in children, finding that these infections generate host responses similar to other viral species, including upregulation of IL6 and ACE2. Our results reveal possible mechanisms influencing SARS-CoV-2 infectivity and COVID-19 clinical outcomes.
Funder
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference82 articles.
1. Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470–473 (2020). 2. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med 382, 727–733 (2020). 3. Baud, D. et al. Real estimates of mortality following COVID-19 infection. Lancet Infect. Dis. 20, 773 (2020). 4. Du, Y. et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. Am. J. Respir. Crit. Care Med. 201, 1372–1379 (2020). 5. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).
Cited by
125 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|